|
1
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
2
|
Parkin DM: Global cancer statistics in the
year 2000. Lancet Oncol. 2:533–543. 2001.PubMed/NCBI
|
|
3
|
Gish RG and Baron A: Hepatocellular
carcinoma (HCC): current and evolving therapies. IDrugs.
11:198–203. 2008.PubMed/NCBI
|
|
4
|
Llovet J, Di Bisceglie A, Bruix J, Kramer
B, Lencioni R, Zhu A, Sherman M, Schwartz M, Lotze M, Talwalkar J
and Gores GJ: Design and endpoints of clinical trials in
hepatocellular carcinoma. J Natl Cancer Inst. 100:698–711. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
DuBray BJ Jr, Chapman WC and Anderson CD:
Hepatocellular carcinoma: a review of the surgical approaches to
management. Mo Med. 108:195–198. 2011.PubMed/NCBI
|
|
6
|
Shu X, McCulloch M, Xiao H, Broffman M and
Gao J: Chinese herbal medicine and chemotherapy in the treatment of
hepatocellular carcinoma:a meta-analysis of randomized controlled
trials. Integr Cancer Ther. 4:219–229. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshida Y, Wang MQ, Liu JN, Shan BE and
Yamashita U: Immunomodulating activity of Chinese medicinal herbs
and Oldenlandia diffusa in particular. Int J Immunopharmacol.
19:359–370. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song Y, Yang J, Bai WL and Ji WY:
Antitumor and immunoregulatory effects of astragalus on
nasopharyngeal carcinoma in vivo and in vitro. Phytother Res.
25:909–915. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu YG and Song LR: Zhong hua ben cao.
Shanghai Sciece and Technology Press; Shanghai: pp. 1530–1533.
1998
|
|
10
|
Zhang YY and Luo JB: Analysis of the
chemical constituents of Hedyotis diffusa. Nan Fang Yi Ke Da Xue
Xue Bao. 28:127–128. 2008.(In Chinese).
|
|
11
|
Lee HZ, Bau DT, Kuo CL, Tsai RY, Chen YC
and Chang YH: Clarification of the phenotypic characteristics and
anti-tumor activity of Hedyotis diffusa. Am J Chin Med. 39:201–213.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang W, Li Y and Jiang J: Chemical
constituents from Hedyotis diffusa. Zhongguo Zhong Yao Za Zhi.
34:712–714. 2009.(In Chinese).
|
|
13
|
Lin J, Chen Y, Wei L, Chen X, Xu W, Hong
Z, Sferra TJ and Peng J: Hedyotis Diffusa Willd extract
induces apoptosis via activation of the mitochondrion-dependent
pathway in human colon carcinoma cells. Int J Oncol. 37:1331–1338.
2010.
|
|
14
|
Lin J, Wei L, Xu W, Hong Z, Liu X and Peng
J: Effect of Hedyotis Diffusa Willd extract on tumor
angiogenesis. Mol Med Rep. 4:1283–1288. 2011.
|
|
15
|
Chen L, Zheng C and Du J: Study on
antitumor mechanism of Qingre Xiaozheng drink by molecular docking
method. Chin J Clin Pharmacol Ther. 12:324–328. 2007.
|
|
16
|
Wadler S: Perspectives for cancer
therapies with cdk2 inhibitors. Drug Resist Updat. 4:347–367. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
18
|
Sasaki K, Tsuno NH, Sunami E, Tsurita G,
Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M, et al:
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on
colon cancer cells. BMC Cancer. 10:3702010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Uka K, Aikata H, Takaki S, Kawaoka T,
Saneto H, Miki D, Takahashi S, Toyota N, Ito K and Chayama K:
Systemic gemcitabine combined with intra-arterial low-dose
cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma:
Seven cases. World J Gastroenterol. 14:2602–2608. 2008. View Article : Google Scholar
|
|
20
|
Hutchins LF, Green SJ, Ravdin PM, Lew D,
Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE and Osborne CK:
Randomized, controlled trial of cyclophosphamide, methotrexate, and
fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil
with and without tamoxifen for high-risk, node-negative breast
cancer: treatment results of Intergroup Protocol INT-0102. J Clin
Oncol. 23:8313–8321. 2005. View Article : Google Scholar
|
|
21
|
Shapiro WR, Green SB, Burger PC, Selker
RG, VanGilder JC, Robertson JT, Mealey J Jr, Ransohff J and Mahaley
MS Jr: A randomized comparison of intra-arterial versus intravenous
BCNU, with or without intravenous 5-fluorouracil, for newly
diagnosed patients with malignant glioma. J Neurosurg. 76:772–781.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsai WS, Hsieh PS, Yeh CY, Chiang JM, Tang
R, Chen JS, Changchien CR and Wang JY: Impact of
chemotherapy-related prognostic factors on long-term survival in
patients with stage III colorectal cancer after curative resection.
Int J Clin Oncol. Jan 20–2012.(Epub ahead of print). View Article : Google Scholar
|
|
23
|
Stehlin JS Jr, de Ipolyi PD, Greeff PJ,
McGaff CJ Jr, Davis BR and McNary L: Treatment of cancer of the
liver. Twenty years’ experience with infusion and resection in 414
patients. Ann Surg. 208:23–35. 1988.
|
|
24
|
Wang W, Cassidy J, O’Brien V, Ryan KM and
Collie-Duguid E: Mechanistic and predictive profiling of
5-fluorouracil resistance in human cancer cells. Cancer Res.
64:8167–8176. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Regazzoni S, Pesce G, Marini G, Cavalli F
and Goldhirsch A: Low-dose continuous intravenous infusion of
5-fluorouracil for metastatic breast cancer. Ann Oncol. 7:807–813.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cameron DA, Gabra H and Leonard RC:
Continuous 5-fluorouracil in the treatment of breast cancer. Br J
Cancer. 70:120–124. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lokich J, Bothe A, Fine N and Perri J:
Phase I study of protracted venous infusion of 5-fluorouracil.
Cancer. 48:2565–2568. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lemon HM: Reduction of 5-fluorouracil
toxicity in man with retention of anticancer effects by prolonged
intravenous administration in 5% dextrose. Cancer Chemother Rep.
8:97–101. 1960.PubMed/NCBI
|
|
29
|
Ng JS, Cameron DA and Leonard RC:
Infusional 5-fluorouracil in breast cancer. Cancer Treat Rev.
20:357–364. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huan S, Pazdur R, Singhakowinta A, Samal B
and Vaitkevicius VK: Low-dose continuous infusion 5-fluorouracil
evaluation in advanced breast carcinoma. Cancer. 63:419–422. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Munoz R, Man S, Shaked Y, Lee CR, Wong J,
Francia G and Kerbel RS: Highly efficacious nontoxic preclinical
treatment for advanced metastatic breast cancer using combination
oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res.
66:3386–3391. 2006. View Article : Google Scholar
|
|
32
|
Iwamoto H, Torimura T, Nakamura T,
Hashimoto O, Inoue K, Kurogi J, Niizeki T, Kuwahara R, Abe M, Koga
H, et al: Metronomic S-1 chemotherapy and vandetanib: An
efficacious and nontoxic treatment for hepatocellular carcinoma.
Neoplasia. 13:187–197. 2011.PubMed/NCBI
|
|
33
|
Tanioka H, Tsuji A, Morita S, Horimi T,
Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K and Tanimoto
M: Combination chemotherapy with continuous 5-fluorouracil and
low-dose cisplatin infusion for advanced hepatocellular carcinoma.
Anticancer Res. 23:1891–1897. 2003.PubMed/NCBI
|
|
34
|
Ueshima K, Kudo M, Takita M, Nagai T,
Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, et al:
Hepatic arterial infusion chemotherapy using low-dose
5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
Oncology. 78:148–153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT,
Sung YC, Liu HT, Hou SM, Wu CH and Chen TK: Hepatic arterial
infusion chemotherapy for hepatocellular carcinoma with tumor
thrombosis of the portal vein. World J Gastroenterol. 9:2666–2670.
2003.PubMed/NCBI
|
|
36
|
Tang TC, Man S, Xu P, Francia G, Hashimoto
K, Emmenegger U and Kerbel RS: Development of a resistance-like
phenotype to sorafenib by human hepatocellular carcinoma cells is
reversible and can be delayed by metronomic UFT chemotherapy.
Neoplasia. 12:928–940. 2010.PubMed/NCBI
|
|
37
|
Takagawa R, Kunisaki C, Makino H, Kosaka
T, Ono HA, Akiyama H and Shimada H: Efficacy of chemoradiotherapy
with low-dose cisplatin and continuous infusion of 5-fluorouracil
for unresectable squamous cell carcinoma of the esophagus. Dis
Esophagus. 22:482–489. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Konkimalla VB and Efferth T:
Evidence-based Chinese medicine for cancer therapy. J
Ethnopharmacol. 116:207–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gupta S, Zhang D, Yi J and Shao J:
Anticancer activities of Oldenlandia diffusa. J Herb Pharmacother.
4:21–33. 2004. View Article : Google Scholar
|
|
40
|
Koff A, Giordano A, Desai D, Yamashita K,
Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR and Roberts
JM: Formation and activation of a cyclin E-cdk2 complex during the
G1 phase of the human cell cycle. Science. 257:1689–1694. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
D’Urso G, Marraccino RL, Marshak DR and
Roberts JM: Cell cycle control of DNA replication by a homologue
from human cells of the p34cdc2 protein kinase. Science.
250:786–791. 1990.PubMed/NCBI
|
|
42
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Weinberg RA: E2F and cell proliferation: a
world turned upside down. Cell. 85:457–459. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nevins JR: The Rb/E2F pathway and cancer.
Hum Mol Genet. 10:699–703. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Matsuda Y: Molecular mechanism underlying
the functional loss of cyclindependent kinase inhibitors p16 and
p27 in hepatocellular carcinoma. World J Gastroenterol.
14:1734–1740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tin AS, Sundar SN, Tran KQ, Park AH,
Poindexter KM and Firestone GL: Antiproliferative effects of
artemisinin on human breast cancer cells requires the downregulated
expression of the E2F1 transcription factor and loss of E2F1-target
cell cycle genes. Anticancer Drugs. 23:370–379. 2012. View Article : Google Scholar
|
|
47
|
Fang XM, Liu B, Liu YB, Wang JJ, Wen JK,
Li BH and Han M: Acetylbritannilactone suppresses growth via
upregulation of krüppel-like transcription factor 4 expression in
HT-29 colorectal cancer cells. Oncol Rep. 26:1181–1187.
2011.PubMed/NCBI
|
|
48
|
Smith IE, Johnston SR, O’Brien ME, Hickish
TF, de Boer RH, Norton A, Cirkel DT and Barton CM: Low-dose oral
fluorouracil with eniluracil as first-line chemotherapy against
advanced breast cancer: a phase II study. J Clin Oncol.
18:2378–2384. 2000.PubMed/NCBI
|
|
49
|
Wang GY, Li ZB, Shi JX, Wang H, Gao QF,
Gen LF, Zhu JJ and Zhao QS: Oldenlandia diffusa protects against
indomethacin-induced injury of the gastrointestinal mucosa in rats.
Hebei J Tradit Chin Med. 23:70–71. 2001.(In Chinese).
|
